SLC1A5 and colorectal cancer: Interestingly, a recent study revealed that the lncRNA SYTL5-OT4 could suppress the autophagic degradation of SLC1A5, which accounts for the resistance of colorectal cancer to regorafenib or bevacizumab, expanding the scope of targeting SLC1A5 to antiangiogenic therapy (AAT) [162].